More stories

  • in

    Warren Buffett’s Berkshire Hathaway continues to sell HP shares, reducing stake to 5.2%

    Shares of HP dipped more than 1% in after-hours trading Monday following the news.
    Berkshire still owns 51.5 million shares of HP, worth about $1.6 billion.

    Warren Buffett tours the floor ahead of the Berkshire Hathaway Annual Shareholder’s Meeting in Omaha, Nebraska.
    David A. Grogan | CNBC

    Warren Buffett’s conglomerate Berkshire Hathaway has reduced its stake in HP to 5.2%, according to a regulatory filing released Monday night.
    The conglomerate previously had a nine-day selling streak in mid-September through early October, bringing down the bet on the printer and PC maker to about 10%.

    Shares of HP dipped more than 1% in after-hours trading Monday following the news.
    Berkshire still owns 51.5 million shares of HP, worth about $1.6 billion based on Monday’s close of $30.37. The Omaha-based investing giant is still the third-largest institutional shareholder of HP, only behind BlackRock and Vanguard, according to FactSet.
    Last month, HP issued first-quarter profit guidance that came below Wall Street estimates, according to LSEG, formerly known as Refinitiv. However, the firm kept its full-year earnings outlook, signaling that the demand in the personal computers market could still be recovering.
    Berkshire initially bought the tech hardware stock in April 2022. The bet, however, hasn’t been lucrative as the stock is still below the level where it was first bought. Shares are up 13% this year, underperforming the Nasdaq Composite, which has rallied nearly 38%.

    Stock chart icon

    Many Buffett watchers had already suspected that the Oracle of Omaha’s intention is to dump the stake entirely.

    The 93-year-old investment icon views stock holdings as pieces of businesses, so he typically closes out a position once he starts selling.
    “We don’t trim positions. That’s just not the way we approach it any more than if we buy 100% of a business,” he once said.Don’t miss these stories from CNBC PRO: More

  • in

    Cigna shares jump on reports of abandoned Humana buyout, plans for $10 billion stock buyback

    Shares of Cigna jumped following reports that the health-care giant has scrapped its plans to buy rival Humana due to disagreements on price.
    Cigna late Sunday also announced plans to buy back $10 billion worth of shares, bringing its total planned repurchases to $11.3 billion.
    The company said in a release that it will consider smaller, “bolt-on” acquisitions in the near term, but did not confirm the reports about its abandoned pursuit of Humana.

    Sopa Images | Lightrocket | Getty Images

    Shares of Cigna jumped Monday following reports that the health-care giant has scrapped its plans to buy rival Humana due to disagreements on price, putting an early end to what would have been one of the largest deals of the decade.
    Cigna late Sunday also announced plans to buy back $10 billion worth of shares, bringing its total planned repurchases to $11.3 billion. The company said in a release that it will consider smaller, “bolt-on” acquisitions in the near term, but did not confirm the reports about its abandoned pursuit of Humana.

    Cigna’s stock closed more than 16% higher Monday, while shares of Humana closed 1% lower.  
    Spokespeople for Cigna and Humana did not immediately respond to CNBC’s requests for comment on the called-off merger, which was first reported by The Wall Street Journal on Sunday. 
    Cigna and Humana couldn’t agree on price and other financial terms of the deal, which would have created a health-care conglomerate with a value exceeding $140 billion, sources familiar with the matter told the Journal. 
    That tie-up would have likely attracted fierce antitrust scrutiny. Shares of the companies fell sharply in late November after the Journal first reported that they were discussing a merger. 
    But Cigna continues to believe in the merits of a tie-up with Humana, the Journal reported Sunday. The combined company would have been focused on improving access to care and lowering costs for consumers, sources told the Journal.

    Jefferies analyst David Windley upgraded shares of Cigna to buy from hold in a Sunday research note, saying the abandoned Humana deal is a “short-term win” for Cigna investors. 
    He added that “taking advantage of a negative reaction to deal reports” by announcing its stock buyback plan on Sunday is “music” to Cigna shareholders’ “value-sensitive ears.” 

    More CNBC health coverage

    Windley noted that shares of Cigna have been down sharply since Nov. 6, when reports emerged about the company exploring a sale of its Medicare Advantage business, which manages government health insurance for people age 65 and older. 
    Investors interpreted that potential sale as a “step to reduce its antitrust exposure in a deal to acquire” Humana, Windley said.
    Don’t miss these stories from CNBC PRO: More

  • in

    Patients regain weight after stopping Eli Lilly’s Zepbound, study says

    Patients who took Eli Lilly’s weight loss drug Zepbound regained around half the weight they lost after stopping the newly approved treatment for a year, according to new data. 
    The data, which are the full results from a study funded by Eli Lilly, suggest that people have to stay on the weekly injection if they want to maintain weight loss. 
    Some Wall Street analysts believe Zepbound, which uses the same active ingredient as Eli Lilly’s diabetes drug Mounjaro, could become the best-selling drug of all time.

    Eli Lilly’s drug tirzepatide was approved for weight loss by the FDA.
    Courtesy of Eli Lilly

    Patients who took Eli Lilly’s weight loss drug Zepbound regained around half the weight they shed after stopping the newly approved treatment for a year, according to data released Monday. 
    The data, which represents the full results from an 88-week study funded by Eli Lilly, suggests that people have to stay on the weekly injection if they want to maintain significant weight loss.

    Shares of Eli Lilly closed more than 2% lower Monday after the data was published in the research journal JAMA. The pharmaceutical giant released initial results from the same study, which was conducted by some Eli Lilly employees and some outside researchers, in July.
    Zepbound, Novo Nordisk’s weight loss injection Wegovy and their blockbuster diabetes counterparts have soared in popularity, and in turn have run in short supply in the U.S. over the past year because they help patients lose substantial weight without surgery. Some Wall Street analysts believe Zepbound, which uses the same active ingredient as Eli Lilly’s diabetes drug Mounjaro, could become the best-selling drug of all time.
    People who discontinue Wegovy and Novo Nordisk’s diabetes medication Ozempic have also regained weight, raising concerns among U.S. health insurers about the high costs involved with long-term coverage of the pricey drugs.
    The study on Eli Lilly’s treatment showed that 670 obese patients without diabetes lost around 20% of their body weight on average after taking Zepbound for 36 weeks. Half of those patients then continued the drug for another 52 weeks, while the other half switched to a placebo for the next year.
    Patients who continued Zepbound lost an additional 6.7% of their weight on average from weeks 36 to 88, while those who stopped taking the drug regained 14.8% of their weight.

    Still, those who discontinued Zepbound still ended the 88-week study with 9.9% less weight than they started with, indicating that they only regained about half the weight they initially lost.
    “If you look at the magnitude of the weight gain, they gain back about half the weight they had originally lost over a one-year period of time,” lead study author Dr. Louis Aronne, an obesity medicine specialist and professor of metabolic research at Weill Cornell Medicine in New York City, said in an interview with CNN.
    About 17% of those who stopped Zepbound maintained at least 80% of their original weight loss, the study said. Meanwhile, 9 in 10 of the people who continued Zepbound were able to maintain at least 80% of the weight they lost.
    Throughout the full 88-week study, health-care professionals encouraged all patients to cut about 500 calories per day from their diet and exercise at least 150 minutes a week. 
    “Patients, providers and the public do not always understand obesity is a chronic disease that often requires ongoing treatment, which can mean that treatment is stopped once weight goals are met,” said Dr. Jeff Emmick, senior vice president of product development at Eli Lilly, in a statement. 
    But Emmick said Monday’s study shows that “continued therapy can help people living with obesity maintain their weight loss.”Don’t miss these stories from CNBC PRO: More

  • in

    Regulators caught Wells Fargo, other banks in probe over mortgage pricing discrimination

    Wells Fargo received an official notice from the Consumer Financial Protection Bureau on problems with its use of mortgage rate discounts, sources said.
    Wells Fargo hired a law firm to grill mortgage bankers whose sales included high levels of the discounts, said the sources.
    Several banks received MRAs about lending practices last year, the CFPB said without naming any of the institutions.
    In their industry review, regulators found “statistically significant disparities” in the rates in which Black and female borrowers got pricing exceptions compared with other customers.

    People pass by a Wells Fargo bank on May 17, 2023 in New York City.
    Spencer Platt | Getty Images

    Wells Fargo was snared in an industrywide probe into mortgage bankers’ use of loan discounts last year, CNBC has learned.
    The discounts, known as pricing exceptions, are used by mortgage personnel to help secure deals in competitive markets. At Wells Fargo, for instance, bankers could request pricing exceptions that typically lowered a customer’s APR by between 25 abd 75 basis points.

    The practice, used for decades across the home loan industry, has triggered regulators’ interest in recent years over possible violations of U.S. fair lending laws. Black and female borrowers got fewer pricing exceptions than other customers, the Consumer Financial Protection Bureau has found.
    “As long as pricing exceptions exist, pricing disparities exist,” said Ken Perry, founder of a Washington-based compliance firm for the mortgage industry. “They’re the easiest way to discriminate against a client.”
    Wells Fargo received an official notice from the CFPB called an MRA, or Matter Requiring Attention, on problems with its discounts, said people with knowledge of the situation. It’s unclear if regulators accused the bank of discrimination or sloppy oversight. The bank’s internal investigation on the matter extended into late this year, said the people.
    Wells Fargo, until recently the biggest player in U.S. mortgages, has repeatedly felt regulators’ wrath over missteps involving home loans. In 2012, it paid more than $184 million to settle federal claims that it charged minorities higher fees and unjustly put them into subprime loans. It was fined $250 million in 2021 for failing to address problems in its mortgage business, and more recently paid $3.7 billion for consumer abuses on products including home loans.
    The behind-the-scenes actions by regulators at Wells Fargo, which hadn’t been reported before, happened in the months before the company announced it was reining in its mortgage business. One reason for that move was the heightened scrutiny on lenders since the 2008 financial crisis.

    Wells Fargo later hired law firm Winston & Strawn to grill mortgage bankers whose sales included high levels of the discounts, said the people, who declined to be identified speaking about confidential matters.

    ‘Proud’ bank

    In response to this article, a company spokeswoman had this statement:
    “Like many in the industry, we take into consideration competitor pricing offers when working with our customers to get a mortgage,” she said. “As part of our renewed focus on supporting underserved communities through our Special Purpose Credit Program, we have spent more than $100 million over the last year to help more minority families achieve and sustain homeownership, including offering deep discounts on mortgage rates.”
    Wells Fargo was “proud to be the largest bank lender to minority families,” she added.
    The bank later had this additional statement: “While we cannot comment on any regulatory matters, we don’t discriminate based on race, gender or age or any other protected basis.”

    Stock chart icon

    Wells Fargo stock vs the Financial Select Sector SPDR Fund

    Regulators have ramped up their crackdown on fair lending violations recently, and other lenders besides Wells Fargo have been involved. The CFPB launched 32 fair lending probes last year, more than doubling the investigations it started since 2020.
    Several banks received MRAs about lending practices last year, the agency said without naming any of the institutions. The CFPB declined to comment for this article.

    ‘Statistically significant’

    The issue with pricing exceptions is that by failing to properly track and manage their use, lenders have run afoul of the Equal Credit Opportunity Act (ECOA) and a related anti-discrimination rule called Regulation B.
    “Examiners observed that mortgage lenders violated ECOA and Regulation B by discriminating against African American and female borrowers in the granting of pricing exceptions,” the CFPB said in a 2021 report.
    The agency found “statistically significant disparities” in the rates in which Black and female borrowers got pricing exceptions compared with other customers.
    After its initial findings, the CFPB conducted more exams and said in a follow-up report this year that problems continued.
    “Institutions did not effectively monitor interactions between loan officers and consumers to ensure that the policies were followed and that the loan officer was not coaching certain consumers and not others regarding the competitive match process,” the agency said.

    Honor system

    In other cases, mortgage personnel failed to explain who initiated the pricing exception or ask for documents proving competitive bids actually existed, the CFPB said.
    That tracks with the accounts of multiple current and former Wells Fargo employees, who likened the process to an “honor system” because the bank seldom verified whether competitive quotes were real.
    “You used to be able to get a half percentage off with no questions asked,” said a former loan officer who operated in the Midwest. “To get an additional quarter point off, you’d have to go to a market manager and plead your case.”
    Pricing exceptions were most common in expensive housing regions of California and New York, according to an ex-Wells Fargo market manager who said he approved thousands of them over two decades at the company. In the years the bank reached for maximum market share, top producers chased loan growth with the help of pricing exceptions, this person said.

    Change of policy

    In an apparent response to the regulatory pressure, Wells Fargo adjusted its policies at the start of this year, requiring hard documentation of competitive bids, said the people. The move coincided with the bank’s decision to focus on offering home loans only to existing customers and borrowers in minority communities.
    Many lenders have made pricing exceptions harder for loan officers to get and improved documentation of the process, though the discounts haven’t disappeared, according to Perry.
    JPMorgan Chase, Bank of America and Citigroup declined to comment when asked whether they had received MRAs or changed their internal policies regarding rate discounts.
    — With reporting from CNBC’s Christina Wilkie.
    Don’t miss these stories from CNBC PRO: More

  • in

    Altice USA in talks to sell Cheddar News to private equity firm Regent

    Altice USA is in discussions to sell Cheddar News to Los Angeles private equity firm Regent LP.
    Altice could be compensated through an earn-out structure in one structure being discussed, sources said.
    Cheddar sold itself to Altice USA in 2019 for $200 million.

    Igor Golovniov | Lightrocket | Getty Images

    Altice USA is in talks to sell the financial news streaming service Cheddar News to LA-based private equity firm Regent LP, according to people familiar with the matter.
    No deal is assured and discussions around structure are still fluid, said the people, who asked not to be named because the talks are private.

    In one iteration of a potential transaction, Altice USA and Regent have discussed a deal where no money will initially exchange hands, one of the people said. Instead, Altice USA would participate in Cheddar’s future performance as part of a so-called “earn out” structure. If Cheddar meets certain performance targets, Altice USA would collect proceeds in future years that could amount to about $50 million based on internal projections, the person said.
    Cheddar was founded in 2016 by Jon Steinberg, who built the company as a business news streaming service aimed at millennials. Altice USA acquired Cheddar for $200 million in 2019. At the time, CEO Dexter Goei told CNBC he made the deal because he was impressed with Steinberg’s ability to grow the business and its advertising revenue. Steinberg stayed with Altice USA through the deal before departing the company in early 2022. Goei stepped down as Altice USA’s CEO later that year.
    Since then, Altice USA, the fourth-largest U.S. cable provider, behind Comcast, Charter and Cox, has looked to shed assets as its stock price has plummeted. Shares have fallen nearly 60% this year amid profit and revenue declines driven by high-speed broadband losses. Altice USA has also considered selling U.S. cable asset Suddenlink but dropped those plans in late 2022.
    Regent specializes in transactions with “creative and legal structures combined with pragmatic seller friendly contractual terms,” according to its website. The private equity fund has experience owning and operating assets in the media sector, acquiring publishing company Sightline Media Group from Tegna in 2016 and Sunset Magazine from Time Inc. in 2017. Regent makes investments in many sectors and acquired the Club Monaco brand from Ralph Lauren in 2021.
    A representative from Altice USA declined to comment. Regent didn’t immediately respond to CNBC’s request for comment.

    The New York Times reported Altice USA was considering selling Cheddar earlier this year.
    Disclosure: Comcast owns NBCUniversal, the parent company of CNBC.
    WATCH: How streaming platforms are starting to consider bundling

    Don’t miss these stories from CNBC PRO: More

  • in

    Fraud in a bottle: How Big Pharma takes on criminals who make millions off counterfeit drugs

    Counterfeiting lifesaving medications is a lucrative criminal enterprise, part of a $431 billion worldwide fraud, according to an estimate from the World Health Organization.
    Gilead Sciences and Johnson & Johnson sued pharmacies, wholesale pharmaceutical distributors and others over a counterfeiting operation that targeted the companies’ HIV drugs. The suits are pending.
    Criminals are targeting other lifesaving drugs, as well, and law enforcement officials say investigations are ongoing.

    In Las Vegas, Lazaro Hernandez was a flamboyant, jet-setting poker player shown in televised tournaments with stacks of colorful chips. But the casually dressed gambler spotted on security cameras with wads of cash at the casino cage was hiding a secret life.
    And federal investigators say he was gambling with people’s lives. Hernandez, they say, oversaw a nationwide $230 million scheme to counterfeit prescription medications, particularly lifesaving HIV drugs, in which pill bottles were altered and sold back to pharmacies at a huge discount.

    Hernandez’s operation altered bottles for Biktarvy, the No. 1 prescribed drug for HIV, as well as Descovy, another HIV medication, and other pharmaceuticals, according to court records. In some cases, the records show, the pills in the bottles were swapped for Seroquel, an antipsychotic drug.
    Hernandez, based in south Florida, gambled with proceeds from the counterfeiting operation, taking private jets to Las Vegas and appearing in numerous poker tournaments, authorities say.
    The drug counterfeiting scheme was part of what the World Health Organization estimates is up to $431 billion in drugs counterfeited worldwide annually. In the U.S., there were 2,121 incidents of counterfeiting in 2022, up 17% from the prior year, according to the Pharmaceutical Security Institute, which tracks industry trends.
    It’s a huge concern for Gilead Sciences, which has made it a priority to find and fight prescription drug diversion and counterfeiting more broadly.
    The company filed a lawsuit in July 2021 against 161 defendants, including pharmacies and wholesale pharmaceutical distributors, accusing them of participating in the scheme to alter the company’s medications Biktarvy and Descovy. Johnson & Johnson filed a similar lawsuit against 27 defendants over its HIV medication Symtuza in April 2022. Other lifesaving drugs have been counterfeited over the past several years, including cancer medications, according to industry experts and law enforcement officials. The suits are pending.

    “These criminals are preying on the most vulnerable,” said Lori Mayall, Gilead’s head of anti-counterfeiting and product security.

    What makes a counterfeit medicine?

    Lori Mayall, Gilead Sciences’ head of anti-counterfeiting and product security.
    Source: CNBC

    In an interview at Gilead’s headquarters in Foster City, California, Mayall explained what constitutes a counterfeit: Altered packaging, a bottle with the wrong tablets, the wrong cap or label and even the leaflet attached which contains important information about the medication.
    Here’s how drug diversion works: A patient fills a prescription for a medication that is worth several thousand dollars but is paid for by Medicare, Medicaid or insurance. The patient then sells it for a fraction of the list price in cash. The buyer, known as an aggregator, removes the patient information, alters the bottle and sells it to the wholesale distributor, who sells it back to the pharmacy.
    Biktarvy has a package list price of $3,795, although most patients’ copays are typically far less or they may obtain significant discounts through the company’s patient assistance programs, according to Gilead.
    In the Gilead counterfeiting operation, which authorities say was overseen by Hernandez, the company discovered it had a potential problem in August 2020. That’s when an independent pharmacy reported that a patient had received a sealed bottle of Biktarvy with Excedrin pills inside, according to the lawsuit.
    The bottle and label appeared to be authentic. Over the next several months, the company received more complaints from patients and pharmacies that other sealed bottles of Biktarvy contained other medications, primarily Seroquel, the antipsychotic. Mayall said counterfeiters had obtained authentic empty bottles, filled them with the wrong pills and packaged them with a counterfeit seal. In one case, she said, a patient temporarily could not walk or talk after taking the Seroquel, but soon recovered.
    “What we’ve seen is our bottles reused,” Mayall said. “They’re cleaned and repackaged to look like genuine Gilead products.”
    Every sale of a prescription medication is supposed to be tracked to provide a chain of custody back to the manufacturer under the federal Drug Supply Chain Security Act. But that hasn’t stopped criminals such as Hernandez from circumventing the process by altering the labels and prescription paperwork and counterfeiting the supply chain documentation, according to law enforcement officials interviewed by CNBC.
    Typically, the crime starts at the street level, where patients are approached outside a homeless shelter or clinic, Mayall said. They’re induced to sell their month’s supply of Biktarvy, for example, for several hundred dollars or less.
    “It’s kind of the reverse of drug dealing on the streets,” Mayall said. “They go to these locations where they know there are patients who receive medicine that’s been dispensed from a pharmacy, and oftentimes these medications are given to the patients through government insurance or through other free drug programs, and they will pay the patients for their medicine and the bottles that come with the medicine.”

    Gilead’s war room

    A “war room” at Gilead Sciences contains thousands of confiscated pill bottles.
    Source: CNBC

    Behind a locked door marked “war room” at Gilead headquarters are tens of thousands of pills and bottles. All were confiscated as counterfeits, Mayall said as she took CNBC on a recent tour. Some of the fakes are obvious because the paperwork contains numerous misspellings.
    Legitimate Gilead medicines are manufactured at the company and then sold to a licensed Gilead distributor, who then sells them to a pharmacy. The counterfeit medications in the war room, most of which were connected to the Hernandez case, were repackaged to look like Gilead products, Mayall said.
    The Gilead lawsuit includes four licensed distributors: Safe Chain Solutions, Scripts Wholesale, ProPharma Distribution and ProVen.
    Of the four, only Safe Chain Solutions, through its attorneys, responded to CNBC’s request for comment.
    Safe Chain Solutions denied claims by Gilead in the suit that it sold or bought counterfeit pills.
    “Safe Chain is a family-owned, full-service wholesale pharmaceutical company that provides a wide range of pharmaceuticals and other health care products to retail pharmacies and other healthcare facilities nationwide,” the statement said. “Independent wholesalers like Safe Chain play a vital role in supplying independent pharmacies, surgical centers, and other retailers with prescription drugs at prices and in volumes they could not obtain from larger wholesalers.”
    The company said it “has never knowingly sold inauthentic drugs or drugs with falsified pedigree documentation, whether manufactured by Gilead or otherwise. It has never altered or fabricated drug transaction histories. Safe Chain and its owners were, at most, victims of this conspiracy.” It said it has shipped more than 100,000 orders with about 2 million units since its founding in 2011 and deals only with licensed suppliers.

    Authorities are investigating schemes in which pill bottles containing prescription drugs are altered and then resold to pharmacies.
    Source: HHS-OIG

    “Safe Chain also communicated extensively with Gilead to investigate concerns about HIV drugs. Indeed, Gilead itself learned about several of these incidents directly from Safe Chain. Safe Chain provided documentation about hundreds of bottles that it sold and further documentation showing what transaction history it had received from its own suppliers. Safe Chain even invited Gilead to inspect its facilities to assure Gilead of its commitment to patient safety and to work collaboratively in investigating these serious issues. These are not the actions of knowing and willful counterfeiters,” the statement said.
    ProPharma Distribution settled the Gilead suit for $3.3 million and agreed to be permanently prohibited from selling Gilead medications, court records show. Details of the full settlement are confidential, according to Gilead attorneys.
    Johnson & Johnson, in a statement to CNBC, said it learned in November 2020 that counterfeit versions of its HIV medication Symtuza were being distributed to three pharmacies in the U.S. The company said it then reported that to the Food and Drug Administration.
    “Counterfeiting of life-saving medications is a criminal act that puts patient lives at risk,” Dr. Dave Anderson, a company vice president, said in the statement. “In addition to the anti-counterfeiting measures and legal action we have taken, we want to remind all stakeholders about the situation and provide specific guidance on how to identify HIV medicines.”

    Criminal schemes

    Geoffrey Potter, a partner with the New York City-based law firm Patterson Belknap Webb & Tyler, represents both Gilead and Johnson & Johnson.
    “We don’t know how much counterfeit medication is in the system because there is no good way of measuring it. But when we do find these schemes, they are very large,” he said.
    In the Hernandez case, which involved distributors throughout the country, Potter said, there was no easy way to determine whether a pill bottle was real or fake just by looking at it.
    “Virtually nobody inspects their medication before taking it, so they wouldn’t be able to tell,” he said.
    Potter said counterfeiters such as Hernandez use sophisticated methods similar to those favored by drug traffickers. That isn’t surprising, since a number of them have been convicted of narcotics-related crimes, he added.
    Stephen Mahmood, assistant special agent in charge at the U.S. Department of Health and Human Services’ Office of Inspector General, or HHS-OIG, said the extent of drug diversion fraud is alarming.

    Stephen Mahmood, assistant special agent in charge at the U.S. Department of Health and Human Services’ Office of Inspector General.
    Source: CNBC

    “I’m saddened and disheartened that the schemes cross the entire United States and territories, but I’m not surprised. Fraud is always evolving,” Mahmood said.
    Depending on the scheme, he said, a pharmacy may or may not know that it is getting a counterfeit drug.
    “Some of the pharmacies are involved with the fraudulent wholesalers. They know exactly what they’re doing,” he said. “Some are unwitting, and they may get a fax from a wholesaler saying, ‘Hey, we have a discounted drug.’ And due to competition and trying to make money, they may buy the drug.”
    In a 2014 case handled by HHS-OIG in Miami, agents used an informant wearing a hidden camera to film a woman, her husband and her adult son in a South Florida apartment altering medication bottles. The video, obtained by CNBC, shows how they used lighter fluid to remove the patient information affixed to the bottle.
    “Because obviously no one is going to sell a drug with someone else’s name on it. And they’re cleaning it to make it look new again,” said Mahmood, describing the video as a “drug diversion in progress.”
    The three were convicted of charges related to the unlicensed distribution of prescription drugs in 2015 and served prison time. All have since been released, and their attorneys did not respond to a request for comment.
    A convicted felon who spoke to CNBC on the condition his identity would not be disclosed and who asked to be referred to as “Julio” said altering medication bottles was his life for about 10 years in South Florida.

    “Julio” says he made millions from the drug counterfeiting business.
    Source: CNBC

    “I was in the pill business. I used to have dealers in the road. The pharmacies buying pills from me, wholesale price,” he said.
    He said patients desperate for cash willingly forgo their essential medication.
    “They will bring it to me. I’ll pay them. I’ll pack it up. I’ll clean it, make it look nice. Then I had a wholesaler who will buy it from me,” he said. He said the wholesaler would then sell the medications back to pharmacies.
    Describing how he cleaned the bottles, he said, “When I get them from the dealer, they come with the label over, with the person’s name. I have a thing that I put — it’s like a liquid that we put on it and we clean it, and we make it look brand new again. It’s got to be brand new so we can resell it.”
    Eventually, he was caught and went to prison.  
    The FDA told CNBC it had no one available to discuss counterfeit drugs, but sent a statement: “The FDA urges the public to obtain prescription drugs only from state-licensed U.S. pharmacies or physicians that are located in the United States, where the FDA and state authorities can assure the quality of drug manufacturing, packaging, distribution and labeling. Non-FDA approved drugs may contain the wrong ingredients, contain too little, too much, or no active ingredient at all, contain other harmful ingredients, or be shipped and/or stored outside of approved conditions.”
    For Lazaro Hernandez, his high-flying days ended abruptly earlier this year. He pleaded guilty in April to conspiracy charges related to distributing adulterated and misbranded drugs and money laundering in connection with a $230 million fraud ring. In June, he was sentenced to 15 years in prison.
    In court documents, one of his attorneys said his “gambling addiction” was a “driving force behind his participation in the criminal conspiracy,” and said Hernandez regularly took cash from his sales of diverted drugs to casinos.
    A different attorney for Hernandez said in an email that she had no comment on the case.
    None of the distributors in the Gilead case have been criminally charged.
    However, Steven Diamanstein, the owner of Scripts Wholesale, based in the Brooklyn borough of New York City, was indicted in June on charges of buying more than $150 million worth of illegally diverted prescription HIV medication and reselling it to pharmacies, according to the indictment and a Justice Department news release. He pleaded not guilty, and his attorney had no comment.
    Other investigations into more counterfeit schemes are pending, law enforcement officials told CNBC, adding that altering pill bottles and the drugs themselves is too lucrative for criminals to slow down.
    “We need to put locks on all the doors and windows to keep the criminals out,” Mayall said. “Right now, it is way too easy for these bottles that have been previously dispensed to patients to make their way back into the supply chain.” More

  • in

    SumUp, a rival to Jack Dorsey’s Block, defies fintech funding slump with $307 million cash injection

    British payments startup SumUp has raised 285 million euros ($306.6 million) in an investment led by Sixth Street Growth and Bain Capital Tech Opportunities.
    SumUp Chief Financial Officer Hermione McKee said the fresh capital gives the company “more firepower to act on opportunities” including acquisitions and new country launches.
    SumUp confirmed the company is worth more than it was when it raised 590 million euros ($635.3 million) at an 8 billion euro ($8.6 billion) valuation in summer 2022.

    SumUp Chief Financial Officer Hermione McKee said the fresh capital gives the company “more firepower to act on opportunities,” including acquisitions and new country launches.

    British payments startup SumUp, known for its small card readers, on Monday announced it has raised 285 million euros ($306.6 million) in a bumper round of funding that values the company north of $8.6 billion.
    Sixth Street Growth, the growth arm of global investment firm Sixth Street, led the investment in SumUp, while existing existing investor Bain Capital Tech Opportunities, fintech investment firm Fin Capital, and debt financing firm Liquidity Group, participated in SumUp’s latest round as well. The round predominantly consisted of equity, though a small portion of the funds was raised as debt.

    SumUp Chief Financial Officer Hermione McKee said the fresh capital gives the company “more firepower to act on opportunities that we see arising over the course of the next two years.”
    “If we think about our geographical expansion, in August we launched Australia as our 36th market globally,” McKee told CNBC in an interview last week ahead of the news.
    “We have this foothold in Latin America and there’s more expansion that can be done there. Then we look at Asia, how do we think about that region, and then obviously opportunities across Africa. There’s so many opportunities globally. We’re constantly assessing this ‘buy versus build’ strategy.”
    With this round, the company says it “continues to build further” on the valuation it attained in the summer of 2022, when SumUp was last valued at 8 billion euros ($8.6 billion) in a 2022 funding round that saw the firm raise a whopping 590 million euros of capital for growth and global expansion. A SumUp spokesperson confirmed the deal is an up round, meaning its valuation is higher than it was previously.
    That’s no small achievement given the state of European technology valuations, which have taken a hammering over the past year as investors flee from tech due to higher interest rates and macroeconomic headwinds.

    According to venture data firm PitchBook, median valuations declined in the third quarter across all stages compared to 2022, with late-stage valuations showing the most resilience and growth-stage the least.

    Earlier this year, existing shareholders in SumUp sold stakes in the firm at a heavily discounted price to its last official valuation. One, online coupons site Groupon, disclosed in a filing with the U.S. Securities and Exchange Commission that it was selling off shares in SumUp at a price that would value the company at just 3.9 billion euros ($4.2 billion).

    M&A shopping spree ahead

    SumUp, which competes primarily with Jack Dorsey’s payments business Block, formerly known as Square, as well as PayPal’s iZettle, FIS’ WorldPay, Stripe, and Adyen, has been expanding into new lines of business lately, not least lending. The company launched a service that enables merchant to apply for a cash advance or business loans up to a certain limit based on their card sales revenues.
    SumUp secured a $100 million credit facility from Victory Park Capital this summer to bolster its cash advance offering. McKee said that the lending product has been going well so far, with the vast majority of its merchants paying back in a timely manner.
    “We’re seeing quick returns on that capital, and merchants that are genuinely supporting their growth. And then they’re able to repay that back in a short time periods for the transaction volume that we see,” McKee said.
    “We haven’t seen any real pullback in terms of repayment data over the course of the last six months,” she added. “Our models are constantly iterating to make sure that that those factors we’re observing don’t become stale.”
    SumUp also launched new point-of-sale offerings, including self-service kiosks that let customers order in stores using a touchscreen interface.
    SumUp recently launched Apple’s Tap to Pay feature in the U.K. and the Netherlands, which enables people to tap their card or phone on a vendor’s iPhone using a smartphone app. It’s also been upgrading its existing point-of-sale systems, with its POS Lite and POS Pros countertop systems that can be paired with SumUp’s card readers.
    Going forward, SumUp plans to explore more merger and acquisition opportunities to help it drive its expansion abroad.
    “M&A is always something that’s on the table,” McKee said. “We have expanded into new geographies in the past with M&A. That’s something we’re always assessing. We have experience in both building an ecosystem as well as buying. And both of these things are available to us, obviously, yes, this just gives us greater optionality and the ability to move quickly, should we see the right opportunity arise.”
    SumUp has no immediate plans to go public, McKee added, as it has ample access to capital in the private markets.
    “I think it’s proven by this round that we actually have access to private pools of capital, so we don’t need to IPO,” she said.
    “We’re constantly improving processes, actually making sure that we are operating at a standard and quality that is appropriate for public markets. But at the same time, this is not something that, you know, is imminent, and around the corner that we’re actively planning for today.” More

  • in

    Fenway moves forward in final talks to invest in PGA Tour’s Saudi deal

    A consortium of investors led by Fenway Sports Group have been chosen for talks to become co-investors in a potential deal between the PGA Tour and Saudi Arabia’s Public Investment Fund.
    The PGA Tour and the Saudi PIF set a deadline of Dec. 31 to finish the deal.
    The PGA Tour said it had received a number of strong investor proposals before narrowing in on the Fenway-led group.

    Tiger Woods wipes his driver grip on the 18th tee box during the first round of the PGA TOUR Champions PNC Championship at The Ritz-Carlton Golf Club on December 17, 2022 in Orlando, Florida.
    Ben Jared | PGA Tour | Getty Images

    A coalition of U.S. sports investors led by Fenway Sports Group have entered the final round of negotiations to become co-investors in a potential deal between the PGA Tour and Saudi Arabia’s Public Investment Fund, the PGA Tour announced on Sunday.
    The Fenway-led consortium, named Strategic Sports Group, includes a variety of investor and private equity names like Celtics majority stake owner Wyc Grousbeck, Chicago Cubs Chairman Tom Ricketts and Cohen Private Ventures, a venture capital firm of New York Mets owner Steve Cohen.

    The investor list also includes Milwaukee Brewers owner Mark Attanasio, Home Depot co-founder Arthur Blank, Liverpool Football Club owner John Henry and Boston Red Sox owner Tom Werner among others.
    The announcement noted that Strategic Sports Group had been selected after a rigorous review of other outside investor offers. The PGA Tour had previously turned down a proposal from TKO majority owner Endeavor Group Holdings.
    As it narrows down its investor pool, the PGA Tour said it would aim to further negotiations with the Saudi PIF in the coming weeks.
    The news comes as time is running out for the PGA Tour to secure the long-awaited deal with the PIF, which owns the DP World Tour and LIV Golf. PGA Tour Commissioner Jay Monahan previously said that the parties would aim to finish the deal by Dec. 31.
    The PGA Tour and the PIF agreed to the merger in June but have gone back and forth on the specific deal terms due partially to resistance from big-name PGA Tour players like Rory McIlroy. The deal also faced probing from lawmakers who are skeptical of Saudi Arabia’s intentions, claiming that the country might be trying to gain influence in the U.S. via sports investment.
    – CNBC’s Jessica Golden contributed to this report. More